Trials / Completed
CompletedNCT05337137
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relatlimab | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2022-05-05
- Primary completion
- 2025-07-05
- Completion
- 2025-11-18
- First posted
- 2022-04-20
- Last updated
- 2026-01-12
Locations
61 sites across 15 countries: United States, Australia, Canada, China, France, Germany, Hong Kong, Italy, Japan, Poland, Puerto Rico, Singapore, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05337137. Inclusion in this directory is not an endorsement.